Which medications in the drug class Tumor Necrosis Factor Blockers are used in the treatment of Iritis and Uveitis?

Updated: Jan 15, 2019
  • Author: Monalisa N Muchatuta , MD, MS; Chief Editor: Gil Z Shlamovitz, MD, FACEP  more...
  • Print

Tumor Necrosis Factor Blockers

The American Uveitis Society has released expert panel recommendations on the use of tumor necrosis factor alpha (TNF-α) inhibitors in ocular inflammatory disorders, which is a widely studied but off-label application for these biologic agents. [17, 18]

These recommendations include the following considerations:

Use of infliximab or adalimumab early in the treatment of patients with vision-threatening ocular manifestations of Behçet disease.

Use of infliximab or adalimumab as second-line therapy in children with vision-threatening uveitis secondary to juvenile idiopathic arthritis for whom methotrexate therapy is ineffective or not tolerated. Methotrexate, if tolerated, can be combined with infliximab.

Use of infliximab and possibly adalimumab can be used as second-line treatment for patients with vision-threatening chronic uveitis caused by seronegative spondyloarthropathy.

Use of infliximab or adalimumab for vision-threatening corticosteroid-dependent disease in patients for whom first-line therapy has failed.

Use of infliximab or adalimumab before etanercept in treatment of ocular inflammatory disease, or switching of patients using etanercept to either infliximab or adalimumab.

Infliximab (Remicade)

Infliximab is a chimeric IgG1κ monoclonal antibody that binds specifically to the soluble and transmembrane forms of TNF-α and inhibits the binding of TNF-α to its receptors.

Adalimumab (Humira)

Adalimumab is a recombinant human IgG1 monoclonal antibody that is specific for human TNF. It reduces inflammation and inhibits progression of structural damage.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!